Get the app
US › Healthcare

Sutro Biopharma (STRO)

US · Healthcare · Biotechnology

$15.48-0.77%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$9.8M
Revenue YoY
-84.6%
Net profit
$-38.5M
EPS
$-2.33
EPS estimate
$-2.04
Net margin
-391.6%

EPS came in at -2.33 against a street estimate of -2.04 — a miss of 14.2%.

Key statistics

Market cap
$258.7M
Forward P/E
10.0
P/B
2.11
Book value
$-6.23
EPS (TTM)
$-16.35
52-week high
$43.85
52-week low
$7.15
50-day MA
$22.93
200-day MA
$22.52
Beta
1.49

Analyst view

Analysts rate Sutro Biopharma a buy (4 buy, 5 hold, 1 sell out of 10) with an average price target of $47.23.

Shareholding

Insiders
2.26%
Institutions
98.72%

Largest institutional holders

FundStake
Bvf Inc7.55%
Affinity Asset Advisors, LLC6.45%
Samsara BioCapital, LLC6.41%
Kynam Capital Management, LP5.26%
Orbimed Advisors LLC4.83%
Vanguard Capital Management, LLC4.34%
Perceptive Advisors LLC4.31%
RA Capital Management, LLC4.31%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sutro Biopharma — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.